Neuroendocrine hormones as prognostic biomarkers in the setting of acute stroke: overcoming the major hurdles. (December 2014)

• Record Type: Journal Article
• Authors: Bustamante, Alejandro; Garcia-Berrocoso, Teresa; Llombart, Victor; Simats, Alba; Giralt, Dolors; Montaner, Joan
• Is Part Of: Expert review of neurotherapeutics. Volume 14:Number 12(2014)
• Page Start: 1391
• Page End: 1403
• Publication Date: 2014-12
• Subjects: Neuropharmacology -- Periodicals; 615.7805
• DOI: 10.1586/14737175.2014.977867
• Languages: English
• ISSNs: 1473-7175

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <p>Stroke represents one of the major causes of disability and mortality worldwide and prediction of outcome represents a challenge for both clinicians and researchers. In the past years, many blood markers have been associated with stroke outcome but despite this evidence, no biomarker is routinely used in stroke management. In this review, we focus on markers of the neuroendocrine system, which represent potential candidates to be implemented in clinical practice. Moreover, we present a systematic review and literature-based meta-analysis for copeptin, a new biomarker of the hypothalamo–pituitary–adrenal axis that has shown additional predictive value over clinical information in a large prospective study. The meta-analysis of the included 7 studies, with more than 2000 patients, reinforced its association with poor outcome (pooled odds ratio: 2.474 [1.678–3.268]) and mortality (pooled OR: 2.569 [1.642–3.495]). We further review the current situation of the topic and next steps to implement these tools by clinicians.</p> </abstract>